Latest Breaking News On - Lewish bender - Page 1 : vimarsana.com

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8

/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of.

Intensity Therapeutics To Present At The 2024 BIO CEO & Investor Conference

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of.

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

FDA provides Study May Proceed letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024 SHELTON, Conn., Jan. 3, 2024.

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Intensity Therapeutics (INTS) Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients blood compared to baseline that was also much larger than a.